- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 215/14 - Radicals substituted by oxygen atoms
Patent holdings for IPC class C07D 215/14
Total number of patents in this class: 468
10-year publication summary
|
40
|
47
|
28
|
34
|
44
|
37
|
32
|
27
|
22
|
4
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 5080 |
21 |
| Gilead Sciences, Inc. | 1879 |
18 |
| Merck Patent GmbH | 5909 |
9 |
| Janssen Pharmaceutica N.V. | 3839 |
8 |
| Merck Sharp & Dohme LLC | 3689 |
8 |
| Santen Pharmaceutical Co., Ltd. | 649 |
7 |
| Novartis AG | 11238 |
6 |
| Neurocrine Biosciences, Inc. | 381 |
6 |
| Nissan Chemical Industries, Ltd. | 1822 |
6 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
6 |
| F. Hoffmann-La Roche AG | 7958 |
5 |
| Allergan, Inc. | 2600 |
5 |
| Toyama Chemical Co., Ltd. | 114 |
5 |
| University College Dublin, National University of Ireland, Dublin | 338 |
5 |
| AstraZeneca AB | 3042 |
4 |
| Centre National de La Recherche Scientifique | 9632 |
4 |
| Agios Pharmaceuticals, Inc | 200 |
4 |
| Alkermes Pharma Ireland Limited | 307 |
4 |
| API Corporation | 211 |
4 |
| Ardelyx, Inc. | 109 |
4 |
| Other owners | 329 |